Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 511 AL 525

Therapeutic Landscape of Early Symptomatic Alzheimer's Disease Translated into Everyday Practice for Geriatric Providers

Bailey-Taylor MJ, Morrow P, Hendrix J, Galluzzi KE, Sharafsaleh G.

Clin Interv Aging. 2026 May 12;21:585263. doi: 10.2147/CIA.S585263. eCollection 2026.

Effect of a Nutraceutical Combination on Oxidative Stress Biomarkers in Healthy Subjects and Patients with Alzheimer's Disease

Jastrząb R, Małecki A, Kmiecik-Małecka E, Gorzkowska A, Kubas K, Widłak-Kargul J, Wolman D, Matkiewicz K, Nowacka-Chmielewska M, Liśkiewicz D, Grabowska K, Grabowski M, Pondel N, Początek G, Kłodowska G, Mytych J.

Nutrients. 2026 Feb 27;18(5):789. doi: 10.3390/nu18050789.

A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA

Reiman EM, Alexander RC, Langbaum JB, Aisen PS, Ashton N, Atri A, Barbarino P, Byrd GS, Feldman HH, Fowler NR, Ghisays V, Grill JD, Hassenstab J, Heaton GR, Herring WL, Jack CR Jr, Johnson SC, Karlawish J, Keach NL, Kivipelto M, Krumholz HM, Largent EA, MaGee-Rodgers T, McDade E, Mielke MM, Molina-Henry D, Petersen RC, Rabinovici GD, Ritchie C, Schindler SE, Sperling RA, Suárez-Calvet M, Vradenburg G, Weiner MW, Welsh-Bohmer KA, Zetterberg H, Zuendel MT, Mattke S, Cummings JL.

Lancet Neurol. 2026 Mar;25(3):268-278. doi: 10.1016/S1474-4422(25)00483-1.

Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives

Zainuddin MS, Pamidi N, Azman AS, Bai Magalingam K, Bhuvanendran S.

Redox Rep. 2026 Dec 31;31(1):2677396. doi: 10.1080/13510002.2026.2677396. Epub 2026 May 26.

Eligibility for lecanemab treatment in a French memory clinic setting

Vrillon A, Götze K, Dumurgier J, Cognat E, Hourrègue C, Munoz-Musat E, Decaix T, Hugon J, Estrada J, Sebbagh M, Bouaziz-Amar É, Lilamand M, Paquet C.

J Neurol. 2026 Mar 23;273(4):228. doi: 10.1007/s00415-026-13760-x.

Should all MCI with Alzheimer's biological diagnosis receive anti-amyloid therapy?

Rossini PM, Pappalettera C.

Cell Death Dis. 2026 Feb 10;17(1):212. doi: 10.1038/s41419-026-08456-z.

Brain connectivity as a new target for Alzheimer's disease therapy?

Pini L, Allali G, Imbimbo BP, Germani M, Corbetta M.

Brain. 2026 Feb 7;149(2):432-438. doi: 10.1093/brain/awaf404.

A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease

Chen T, Hutchison RM, Rubel C, Murphy J, Xie J, O'Gorman J, Dent G, Molenberghs G, Sormani MP, Hendrix S, Hansson O, Aisen P, Haeberlein SB, Tian Y.

J Prev Alzheimers Dis. 2026 Feb;13(2):100458. doi: 10.1016/j.tjpad.2025.100458. Epub 2026 Jan 1.

Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease

Kupiec JW, Porsteinsson AP, Turner RS, Hendrix S, Mallinckrodt C, Khan A, Cohen I, Liss J, Clarnette R, Park KH, Hernandez AM, Burns LH.

J Prev Alzheimers Dis. 2026 Mar;13(3):100469. doi: 10.1016/j.tjpad.2025.100469. Epub 2026 Jan 6.

Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis

Wilson JM, Dage JL, Qian HR, Irelan CL, Crowder HS, Duffin KL, Mintun M, Brooks DA, Gerstein HC, Bethel MA.

Alzheimers Dement. 2026 Apr;22(4):e71391. doi: 10.1002/alz.71391.

The myth of digital biomarkers in Alzheimer's disease: how to make them a reality

Au R, Gifford KA, Paschalidis IC, Wighton P, Levin M, Imam F, Bose N, Pratap A.

Curr Opin Psychiatry. 2026 Jul 1;39(4):331-338. doi: 10.1097/YCO.0000000000001089. Epub 2026 Apr 29.

Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study

Liao W, Yu Q, Chen B, Chen H, Zou L, Xie H, Chen H, Wang C, Li Y, Gao X, Guo H, Yang Y, She Z, Zeng Q, Zhang Z, Li G, Feng S, Lin H, Ouyang J, Liang J, Ao W, Zeng Q, Liu Z, Weng H, Huang H, Zhu F, Liu R, Wang Y, Yu D, Li X, Mai Y, Jiang S, Tu Y, Li Z, Liu J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2026 Mar;22(3):e71231. doi: 10.1002/alz.71231.

Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease

Cummings JL, Agadjanyan MG, Barry M, Corey L, Doody R, Hendrix S, Mattke S, Mattsson-Carlgren N, McDade E, Menetski JP, Mohs RC, Partrick KA, Petrovsky N, Selkoe DJ, Silva D, Sperling RA, Tiede B, Vradenburg G.

Nat Med. 2026 Apr;32(4):1223-1232. doi: 10.1038/s41591-026-04305-w. Epub 2026 Apr 3.

A multi-target therapeutic framework for Alzheimer's disease: an integrative mechanistic review

Bajinka O, Jallow L, Ozdemir G.

Neuroscience. 2026 Mar 5;596:143-157. doi: 10.1016/j.neuroscience.2026.01.010. Epub 2026 Jan 9.

Tau in Alzheimer's disease: Shaping the future patient journey

Mummery CJ, Li-Hsian CC, Lasagna-Reeves CA, Ossenkoppele R, Rowe CC, Scharre DW, Wang H, Kyaga S, Cummings JL.

J Prev Alzheimers Dis. 2026 Feb;13(2):100447. doi: 10.1016/j.tjpad.2025.100447. Epub 2026 Jan 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias